{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:19:48Z","timestamp":1790248788052,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000223","name":"Muscular Dystrophy Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["FDN143251"],"award-info":[{"award-number":["FDN143251"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1038\/s41434-020-0156-6","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T12:02:54Z","timestamp":1591012974000},"page":"407-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy"],"prefix":"10.1038","volume":"27","author":[{"given":"Kasia","family":"Dzierlega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"key":"156_CR1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","volume":"21","author":"SJ Moat","year":"2013","unstructured":"Moat SJ, Bradley DM, Salmon R, Clarke A, Hartley L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet. 2013;21:1049\u201353.","journal-title":"Eur J Hum Genet"},{"key":"156_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/184393","volume":"2011","author":"A Nakamura","year":"2011","unstructured":"Nakamura A, Takeda S. Mammalian models of Duchenne muscular dystrophy: pathological characteristics and therapeutic applications. J Biomed Biotechnol. 2011;2011:1\u20139.","journal-title":"J Biomed Biotechnol."},{"key":"156_CR3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1006\/geno.1993.1225","volume":"2","author":"RG Roberts","year":"1993","unstructured":"Roberts RG, Coffey AJ, Bobrow M, Bentley DR. Exon structure of the human dystrophin gene. Genomics. 1993;2:536\u20138.","journal-title":"Genomics."},{"key":"156_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0135189","volume":"10","author":"J Juan-Mateu","year":"2015","unstructured":"Juan-Mateu J, Gonzalez-Quereda L, Rodriguez MJ, Baena M, Verdura E, Nascimento A, et al. DMD mutations in dystrophinopathy families: a step forward in genotype-phenotype correlations. PLoS One. 2015;10:1\u201321.","journal-title":"PLoS One."},{"key":"156_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0703-4","volume":"12","author":"M Okubo","year":"2017","unstructured":"Okubo M, Goto K, Komaki H, Nakamura H, Mori-Yoshimura M, Hayashi YK, et al. Comprehensive analysis for genetic diagnosis of dystrophinopathies in Japan. Orphanet J Rare Dis. 2017;12:1\u20137.","journal-title":"Orphanet J Rare Dis"},{"key":"156_CR6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003;2:731\u201340.","journal-title":"Lancet Neurol"},{"key":"156_CR7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"1","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988;1:90\u201395.","journal-title":"Genomics."},{"key":"156_CR8","first-page":"1223","volume":"5","author":"Q Gao","year":"2016","unstructured":"Gao Q, McNally EM. The dystrophin complex: structure, function and implications for therapy. Compr Physiol. 2016;5:1223\u201339.","journal-title":"Compr Physiol"},{"key":"156_CR9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/jnnp.57.4.426","volume":"57","author":"M Uchino","year":"1994","unstructured":"Uchino M, Teramoto H, Naoe H, Yoshioka K, Miike T, Ando M. Localization and characterization of dystrophin in the central nervous system of controls and patients with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 1994;57:426\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"156_CR10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0092-8674(95)90344-5","volume":"80","author":"KP Campbell","year":"1995","unstructured":"Campbell KP. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell. 1995;80:675\u20139.","journal-title":"Cell."},{"key":"156_CR11","first-page":"229","volume":"2007","author":"KR Wagner","year":"1772","unstructured":"Wagner KR, Lechtzin N, Judge DP. Current treatment of adult Duchenne muscular dystrophy. Biochimica et Biophys Acta. 1772;2007:229\u201337.","journal-title":"Biochimica et Biophys Acta"},{"key":"156_CR12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0960-8966(94)00048-E","volume":"5","author":"E Backman","year":"1995","unstructured":"Backman E, Henriksson KG. Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 1995;5:233\u201341.","journal-title":"Neuromuscul Disord."},{"key":"156_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1067\/mpd.2001.109601","volume":"138","author":"WD Biggar","year":"2001","unstructured":"Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatrics. 2001;138:45\u201350.","journal-title":"J Pediatrics"},{"key":"156_CR14","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(74)90071-3","volume":"304","author":"DB Drachman","year":"1974","unstructured":"Drachman DB, Toyka KV, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet. 1974;304:1409\u201312.","journal-title":"Lancet."},{"key":"156_CR15","first-page":"1","volume":"1","author":"AY Manzur","year":"2008","unstructured":"Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2008;1:1\u201333.","journal-title":"Cochrane Database Syst Rev"},{"key":"156_CR16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1440-1789.2009.01028.x","volume":"29","author":"A Nakamura","year":"2009","unstructured":"Nakamura A, Takeda S. Exon-skipping therapy for Duchenne muscular dystrophy. Neuropathology. 2009;29:494\u2013501.","journal-title":"Neuropathology."},{"key":"156_CR17","first-page":"71","volume":"1175","author":"H Heemskerk","year":"2009","unstructured":"Heemskerk H, Winter CL, Ommen GJB, Deutekom JCT, Aartsma-Rus A. Development of antisense-mediated exon skipping as a treatment for Duchenne muscular dystrophy. Oligonucleotide Therap. 2009;1175:71\u201379.","journal-title":"Oligonucleotide Therap"},{"key":"156_CR18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/hmg\/ddg100","volume":"12","author":"A Aartsma-Rus","year":"2003","unstructured":"Aartsma-Rus A, Janson AAM, Kaman WE, Bremmer-Bout M, Dunnen JTD, Baas F, et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet. 2003;12:907\u201314.","journal-title":"Hum Mol Genet"},{"key":"156_CR19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ana.21627","volume":"65","author":"T Yokota","year":"2009","unstructured":"Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol. 2009;65:667\u201376.","journal-title":"Ann Neurol."},{"key":"156_CR20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/jgm.295","volume":"4","author":"CJ Mann","year":"2002","unstructured":"Mann CJ, Honeyman K, McClorey G, Fletcher S, Wilton SD. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med. 2002;4:644\u201354.","journal-title":"J Gene Med"},{"key":"156_CR21","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.4155\/fmc.15.116","volume":"7","author":"A Guncay","year":"2015","unstructured":"Guncay A, Yokota T. Antisense oligonucleotide drugs for Duchenne muscuklar dystrophy: how far have we come and what does the future hold. Future Med Chem. 2015;7:1631\u20135.","journal-title":"Future Med Chem"},{"key":"156_CR22","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/humu.21114","volume":"30","author":"KM Flanigan","year":"2009","unstructured":"Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Gappmaier E, Howard MT, et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat. 2009;30:1657\u201366.","journal-title":"Hum Mutat."},{"key":"156_CR23","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","volume":"76","author":"YY Syed","year":"2016","unstructured":"Syed YY. Eteplirsen: first global approval. Drugs. 2016;76:1699\u2013704.","journal-title":"Drugs."},{"key":"156_CR24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQ Lim","year":"2017","unstructured":"Lim KRQ, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Dev Ther. 2017;11:533\u201345.","journal-title":"Drug Des Dev Ther"},{"key":"156_CR25","unstructured":"U.S National Library of Medicine. Study of SRP-4045 and SRP-4053 in DMD Patients (ESSENCE). 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02500381."},{"key":"156_CR26","unstructured":"Nippon Shinyaku Co. LTD. Marketing authorization in Japan of VILTEPSO intravenous infusion 250 mg for the treatment of Duchenne muscular dystrophy. 2020. https:\/\/www.nippon-shinyaku.co.jp."},{"key":"156_CR27","unstructured":"Komaki H, Takeshima Y, Matsumura T, Ozasa S, Funato M, Egawa Y, et al. (n.d.). A Japanese Phase I\/II study of NS-065\/NCNP-01 (Viltolarsen), Exon 52 skipping drug, in patients with Duchenne muscular dystrophy\u2014a dose-finding study.\u00a0Mendoza: Poster presented at the\u00a023rd International Annual\u00a0Congress\u00a0of the\u00a0World Muscle Society; 2018."},{"key":"156_CR28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1517\/14712598.2012.693469","volume":"12","author":"T Yokota","year":"2012","unstructured":"Yokota T, Duddy W, Echigoya Y, Kolski H. Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients? Expert Opin Biol Ther. 2012;12:1141\u201352.","journal-title":"Expert Opin Biol Ther"},{"key":"156_CR29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/brain\/awq002","volume":"133","author":"MJA Wood","year":"2010","unstructured":"Wood MJA, Gait MJ, Yin H. RNA-targeted splice-correction therapy for neuromuscular disease. Brain. 2010;133:957\u201372.","journal-title":"Brain."},{"key":"156_CR30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/nat.2013.0461","volume":"24","author":"K Siva","year":"2014","unstructured":"Siva K, Covello G, Denti MA. Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases. Nucleic Acid Therap. 2014;24:69\u201386.","journal-title":"Nucleic Acid Therap."},{"key":"156_CR31","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.mt.6300095","volume":"15","author":"SD Wilton","year":"2007","unstructured":"Wilton SD, Fall AM, Harding PL, McClorey G, Coleman C, Fletcher S. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther. 2007;15:1288\u201396.","journal-title":"Mol Ther."},{"key":"156_CR32","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","volume":"90","author":"A Dominski","year":"1993","unstructured":"Dominski A, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl Acad Sci. 1993;90:8673\u20137.","journal-title":"Proc. Natl Acad Sci."},{"key":"156_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/mtna.2016.89","volume":"5","author":"RW Slijkerman","year":"2016","unstructured":"Slijkerman RW, Vache C, Dona M, Garcia-Garcia G, Claustres M, Hetterschijt L, et al. Antisense oligonucleotide-based splice correction for ush2a-associated retinal degeneration caused by a frequent deepintronic mutation. Mol Ther Nucleic Acids. 2016;5:1\u201310.","journal-title":"Mol Ther Nucleic Acids"},{"key":"156_CR34","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/15079","volume":"17","author":"J Taylor","year":"1999","unstructured":"Taylor J, Zhang Q, Wyatt J, Dean NM. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol. 1999;17:1097\u20131100.","journal-title":"Nat Biotechnol."},{"key":"156_CR35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/978-1-4939-8651-4_33","volume":"1828","author":"GK Arthur","year":"2018","unstructured":"Arthur GK, Cruse G. Exon skipping of Fc\u03b5RI\u03b2 for allergic diseases. Methods Mol Biol. 2018;1828:503\u201318.","journal-title":"Methods Mol Biol"},{"key":"156_CR36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1083\/jcb.201207087","volume":"199","author":"F Rigo","year":"2012","unstructured":"Rigo F, Hua Y, Krainer AR, Bennett CF. Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol. 2012;199:21\u201325.","journal-title":"J Cell Biol"},{"key":"156_CR37","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ejhg.2010.4","volume":"18","author":"A Aartsma-Rus","year":"2010","unstructured":"Aartsma-Rus A, Singh K, Fokkema IFAC, Ginjaar LB, Ommen GJV, Dunnen JTV. et al. Therapeutic exon skipping for dysferlinopathies?. Eur J Hum Genet. 2010;18:889\u201394.","journal-title":"Eur J Hum Genet"},{"key":"156_CR38","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2174\/156802607780487740","volume":"7","author":"JE Summerton","year":"2007","unstructured":"Summerton JE. Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr Topics Med Chem. 2007;7:651\u201360.","journal-title":"Curr Topics Med Chem"},{"key":"156_CR39","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/mt.2010.72","volume":"18","author":"H Heemskerk","year":"2010","unstructured":"Heemskerk H, Winter C, Kuik P, Heuvelmans N, Sabatelli P, Rimessi P, et al. Preclinical PK and PD studies on 2\u2032-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model. Mol Ther. 2010;18:1210\u20137.","journal-title":"Mol Ther."},{"key":"156_CR40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.addr.2015.05.008","volume":"87","author":"R Kole","year":"2015","unstructured":"Kole R, Krieg AM. Exon skipping therapy for Duchenne muscular dystrophy. Adv Drug Deliv Rev. 2015;87:104\u20137.","journal-title":"Adv Drug Deliv Rev."},{"key":"156_CR41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00431-018-3272-1","volume":"178","author":"N Hilhorst","year":"2019","unstructured":"Hilhorst N, Spanoudi-Kitrimi I, Goemans N, Morren MA. Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study. Eur J Pediatrics. 2019;178:253\u20138.","journal-title":"Eur J Pediatrics"},{"key":"156_CR42","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.2016.16437","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim AS, Avorn J. Approving a problematic muscular dystrophy drug: implications for FDA policy. JAMA. 2016;316:2357\u20138.","journal-title":"JAMA."},{"key":"156_CR43","first-page":"179","volume":"26","author":"T Yokota","year":"2007","unstructured":"Yokota T, Duddy W, Partridge T. Optimizing exon skipping therapies for DMD. Acta Myol. 2007;26:179\u201384.","journal-title":"Acta Myol"},{"key":"156_CR44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm1345","volume":"12","author":"J Alter","year":"2006","unstructured":"Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med. 2006;12:175\u20137.","journal-title":"Nat Med."},{"key":"156_CR45","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.coph.2005.07.001","volume":"5","author":"A Amantana","year":"2005","unstructured":"Amantana A, Iversen PL. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.\u00a0Curr Opin Pharmacol. 2005;5:550\u20135.","journal-title":"Curr Opin Pharmacol"},{"key":"156_CR46","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/hmg\/ddg196","volume":"12","author":"BL Gebski","year":"2003","unstructured":"Gebski BL, Mann CJ, Fletcher S, Wilton SD. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet. 2003;12:1801\u201311.","journal-title":"Hum Mol Genet"},{"key":"156_CR47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.mcn.2004.03.005","volume":"27","author":"GPH Dietz","year":"2004","unstructured":"Dietz GPH, B\u00e4hr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci. 2004;27:85\u2013131.","journal-title":"Mol Cell Neurosci."},{"key":"156_CR48","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1021\/nn4057269","volume":"8","author":"DM Copolovici","year":"2014","unstructured":"Copolovici DM, Langel K, Eriste E, Langel U. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano. 2014;8:1972\u201394.","journal-title":"ACS Nano."},{"key":"156_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0198897","volume":"13","author":"AM Blain","year":"2018","unstructured":"Blain AM, Greally E, McClorey G, Manzano R, Betts CA, Godfrey C, et al. Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-\/-mdx mouse models of Duchenne muscular dystrophy. PLoS ONE. 2018;13:1\u201322.","journal-title":"PLoS ONE."},{"key":"156_CR50","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T, Urasawa N, Lim KRQ, Trieu N. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. PNAS. 2017;114:4213\u20138.","journal-title":"PNAS."},{"key":"156_CR51","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ajpath.2012.04.006","volume":"181","author":"B Wu","year":"2012","unstructured":"Wu B, Lu P, Cloer C, Shaban M, Grewal S, Milazi S, et al. Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am J Pathol. 2012;181:392\u2013400.","journal-title":"Am J Pathol."},{"key":"156_CR52","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1021\/bc8001437","volume":"19","author":"YF Li","year":"2008","unstructured":"Li YF, Marcos PA. Design and synthesis of dendritic molecular transporter that achieves efficient in vivo delivery of morpholino antisense oligo. Bioconjugate Chem. 2008;19:1464\u201370.","journal-title":"Bioconjugate Chem."},{"key":"156_CR53","unstructured":"U.S National Library of Medicine. A phase 2 study for dose determination of SRP-5051, then dose expansion in patients with Duchenne muscular dystrophy amenable to exon 51-skipping treatment. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04004065."},{"key":"156_CR54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/mt.2010.212","volume":"19","author":"JK Kang","year":"2010","unstructured":"Kang JK, Malerba A, Popplewell L, Foster K, Dickson G. Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. Mol Ther. 2010;19:159\u201364.","journal-title":"Mol Ther."},{"key":"156_CR55","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/mt.2009.38","volume":"17","author":"B Wu","year":"2009","unstructured":"Wu B, Li Y, Morcos PA, Doran TJ, Lu P, Lu QL. Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther. 2009;17:864\u201371.","journal-title":"Mol Ther."},{"key":"156_CR56","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","volume":"378","author":"S Cirak","year":"2011","unstructured":"Cirak S, Arechavala-Gomza V, Guglieri M, Feng L, Torelli S, Anthony K, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378:595\u2013605.","journal-title":"Lancet."},{"key":"156_CR57","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm.3765","volume":"21","author":"A Goyenvalle","year":"2015","unstructured":"Goyenvalle A, Griffith G, Babbs A, El Andaloussi S, Ezzat K, Avril A, et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Na Med. 2015;21:270\u20135.","journal-title":"Na Med."},{"key":"156_CR58","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/nat.2018.0773","volume":"29","author":"L Echevarr\u0131\u00b4a","year":"2019","unstructured":"Echevarr\u00eda L, Aupy P, Relizani K, Bestetti T, Griffith G, Blandel F, et al. Evaluating the impact of variable phosphorothioate content in tricyclo-dna antisense oligonucleotides in a duchenne muscular dystrophy mouse model. Nucl Acid Ther. 2019;29:148\u201360.","journal-title":"Nucl Acid Ther"},{"key":"156_CR59","unstructured":"U.S Food and Drug Administration. FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation. 2019. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation."},{"key":"156_CR60","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","volume":"25","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila M, et al. Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy. Mol Ther. 2017;25:2561\u201372.","journal-title":"Mol Ther."},{"key":"156_CR61","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1038\/mt.2010.186","volume":"18","author":"Y Aoki","year":"2010","unstructured":"Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, et al. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther. 2010;18:1995\u20132005.","journal-title":"Mol Ther."},{"key":"156_CR62","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79:257\u201371.","journal-title":"Ann Neurol."},{"key":"156_CR63","unstructured":"Refusal of marketing authorization for Exondys (eteplirsen). Eur Med Agency. 2018;1:1\u20132."},{"key":"156_CR64","doi-asserted-by":"crossref","first-page":"S22.001","DOI":"10.1212\/WNL.90.15_supplement.S22.001","volume":"90","author":"F Muntoni","year":"2018","unstructured":"Muntoni F, Frank D, Sardone V, Morgan J, Schnell F, Charleston J, et al. Golodirsen induces exon skipping leading to Sarcolemmal dystrophin expression in Duchenne muscular dystrophy patients with mutations amenable to exon 53 skipping. Neurology. 2018;90:S22.001.","journal-title":"Neurology."},{"key":"156_CR65","unstructured":"U.S. National Library of Medicine. Phase I\/II study of SRP-4053 in DMD patients. 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02310906."},{"key":"156_CR66","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.omtn.2018.09.017","volume":"13","author":"N Watanabe","year":"2018","unstructured":"Watanabe N, Nagata T, Satou Y, Masuda S, Saito T, Kitagawa H, et al. NS-065\/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2018;13:442\u20139.","journal-title":"Mol Ther Nucleic Acids"},{"key":"156_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0120058","volume":"10","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Mouly V, Garcia L, Yokota T, Duddy W. In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in duchenne muscular dystrophy. PLoS ONE. 2015;10:1\u201324.","journal-title":"PLoS ONE"},{"key":"156_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aan0713","volume":"10","author":"H Komaki","year":"2018","unstructured":"Komaki H, Nagata T, Saito T, Masuda S, Takeshita E, Sasaki M, et al. Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Sci Transl Med. 2018;10:1\u201311.","journal-title":"Sci Transl Med."},{"key":"156_CR69","unstructured":"Clemens P, Rao V, Connolly A, Harper A, Mah J, Smith E, et al. A phase II, dose finding study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of NS-065\/NCNP-01 (Viltolarsen) in boys with Duchenne muscular dystrophy (DMD). Mendoza: Poster presented at the\u00a023rd International Annual\u00a0Congress\u00a0of the\u00a0World Muscle Society;\u00a02018."},{"key":"156_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-0556-4-1","volume":"4","author":"AM Fall","year":"2006","unstructured":"Fall AM, Johnsen R, Honeyman K, Iversen P, Fletcher S, Wilton SD. Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genetic Vaccines Ther. 2006;4:1\u201312.","journal-title":"Genetic Vaccines Ther"},{"key":"156_CR71","first-page":"1","volume":"111","author":"BM Nichols","year":"2016","unstructured":"Nichols BM, Aoki Y, Kuraoka M, Lee JJA, Takeda S, Yokota T. Multi-exon skipping using cocktail antisense oligonucleotides in the Canine X-linked muscular dystrophy. J Vis Exp. 2016;111:1\u201315.","journal-title":"J Vis Exp."},{"key":"156_CR72","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ymthe.2019.07.012","volume":"27","author":"Y Echigoya","year":"2019","unstructured":"Echigoya Y, Lim KRQ, Melo D, Bao B, Trieu N, Mizobe Y, et al. Exons 45\u201355 skipping using mutation-tailored cocktails of antisense morpholinos in the DMD gene. Mol Ther. 2019;27:2005\u201317.","journal-title":"Mol Ther."},{"key":"156_CR73","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000008089","volume":"42","author":"M Yazaki","year":"1999","unstructured":"Yazaki M, Yoshida K, Nakamura A, Koyama J, Nanba T, Ohori N, et al. Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol. 1999;42:145\u20139.","journal-title":"Eur Neurol."},{"key":"156_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/mtna.2014.76","volume":"4","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Aoki Y, Miskew B, Panesar D, Touznik A, Nagata T, et al. Long-term efficacy of systemic multiexon skipping targeting Dystrophin exons 45\u201355 with a cocktail of vivo-morpholinos in Mdx52 Mice. Mol Ther Nucleic Acids. 2015;4:1\u201310.","journal-title":"Mol Ther Nucleic Acids"},{"key":"156_CR75","doi-asserted-by":"crossref","first-page":"13763","DOI":"10.1073\/pnas.1204638109","volume":"109","author":"Y Aoki","year":"2012","unstructured":"Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, et al. Bodywide skipping of exons 45\u201355 in dystrophic mdx52 mice by systemic antisense delivery. PNAS. 2012;109:13763\u20138.","journal-title":"PNAS."},{"key":"156_CR76","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/archneurol.2008.540","volume":"66","author":"T Yokota","year":"2009","unstructured":"Yokota T, Takeda S, Lu QL, Partridge TA, Nakamura A, Hoffman EP. A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol. 2009;66:32\u201338.","journal-title":"Arch Neurol."},{"key":"156_CR77","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/mt.2008.205","volume":"17","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, Van Vliet L, Hirschi M, Janson AAM, Heemskerk H, Winter CLD, et al. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther. 2009;17:548\u201353.","journal-title":"Mol Ther."},{"key":"156_CR78","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/mt.2008.287","volume":"17","author":"LJ Popplewell","year":"2009","unstructured":"Popplewell LJ, Trollet C, Dickson G, Graham IR. Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol Ther. 2009;17:554\u201361.","journal-title":"Mol Ther."},{"key":"156_CR79","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.mt.6300006","volume":"15","author":"PL Harding","year":"2017","unstructured":"Harding PL, Fall AM, Honeyman K, Fletcher S, Wilton SD. The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol Ther. 2017;15:157\u201366.","journal-title":"Mol Ther."},{"key":"156_CR80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jpm7040013","volume":"7","author":"Q Nguyen","year":"2017","unstructured":"Nguyen Q, Yokota T. Immortalized muscle cell model to test the exon skipping efficacy for Duchenne muscular dystrophy. J Pers Med. 2017;7:1\u20139.","journal-title":"J Pers Med."},{"key":"156_CR81","doi-asserted-by":"crossref","first-page":"8174","DOI":"10.1093\/nar\/gku512","volume":"42","author":"T Shino","year":"2014","unstructured":"Shimo T, Tachibana K, Saito K, Yoshida T, Tomita E, Waki R, et al. Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro. Nucleic Acid Res. 2014;42:8174\u201387.","journal-title":"Nucleic Acid Res"},{"key":"156_CR82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2044-5040-1-34","volume":"1","author":"K Mamchaoui","year":"2011","unstructured":"Mamchaoui K, Trollet C, Bigot A, Negroni E, Chaouch S, Wolff A, et al. Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skeletal Muscle. 2011;1:1\u201310.","journal-title":"Skeletal Muscle."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41434-020-0156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41434-020-0156-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41434-020-0156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T19:17:21Z","timestamp":1722971841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-0156-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":82,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1038\/s41434-020-0156-6","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"assertion":[{"value":"16 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}